Sunday, August 30, 2026

Over $7 Billion Flowed Into Robotics Startups Across the US, China, and Europe in Six Months

AI foundation models have triggered a global robotics investment surge, with US, Chinese, and European startups raising billions at valuations once reserved for mature companies. Skild AI's $1.4B January raise set a new benchmark, followed by massive rounds from players in Pittsburgh, Beijing, and Germany. Investors are betting AI-driven robots reach commercial viability by 2027–2028.

LM Salvado
LM Salvado

June 27, 2026

Over $7 Billion Flowed Into Robotics Startups Across the US, China, and Europe in Six Months
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

More than $7 billion flowed into robotics startups across the United States, China, and Europe in the first half of 20261,2,3,4,5,6,7 — as AI foundation models rewrote the investment case for physical automation worldwide.

Skild AI raised $1.4B in January 20261, ten times its $135M Series B from months earlier. The Pittsburgh-based company's round set the tone: investors now price AI-driven robots as near-term commercial bets, not long-horizon experiments.

Chinese startup Shihang Intelligent raised $1B at Series A stage in June5 — a scale once reserved for late-stage companies — as China accelerates its industrial automation push. Germany's Neura Robotics, a leading European humanoid robotics developer, secured up to $1.4B in a Series C that same month4. Mind Robotics closed $500M in March2 and added a $400M follow-on by May3.

Apptronik extended its Series A with $520M in February6, building on $415M raised in 2025. Saronic, developing autonomous maritime vessels, closed a $1.75B Series D in March7.

Billion-dollar valuations at Series A and B are the telling detail. Foundation models trained on unstructured data let robots generalize across tasks. Earlier systems required expensive per-task programming. That bottleneck has narrowed as model capabilities scaled — and capital from San Francisco to Shanghai is following.

M&A is accelerating alongside the funding. Meta acquired Assured Robot Intelligence in May8. Skild AI acquired Zebra Technologies' Robotics Division in April9, expanding enterprise deployment footprint shortly after its own mega-round closed.

For global manufacturers, logistics operators, and defence contractors, robotics is now the clearest near-term path from AI capability to physical-world revenue. The harder test follows: consistent performance outside controlled environments, at the scale needed to justify these valuations in every market from Detroit to Shenzhen.

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Network, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI's Trust Gap: Microsoft-Mistral Ecosystem Expansion Meets a Governance Deficit in Agentic Adoption
Microsoft is deepening its AI platform bet through simultaneous moves — expanding its Mistral partnership (Copilot Studio, Foundry, European infrastructure capacity) and deepening enterprise AI governance ties with Manulife — just as independent research (Google Cloud, VentureBeat, Box) shows enterprises racing toward agentic AI adoption (100% planned within two years) while data access and trust in agent decisions lag badly (average 45% data access, only ~half trust agent outputs). The result is a structural mismatch between platform-vendor momentum and enterprise readiness to actually govern and trust the agents being deployed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
Same entity (Morgan Stanley & Co. LLC), same metric (net_income), same fiscal period (Q1 2026), same observation date (2026-03-31), but vastly different values: $5.567 billion vs. $5.57. These cannot coexist for the same time period. Fact B appears to be a data entry error (possible missing decimal placement: 5.57 should likely be 5,567,000,000 or a per-share figure incorrectly entered as total).
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,257 source documents archived
Query this data → isubstrate.com